Skip to main content

Advertisement

SpringerLink
Log in

Consensus document: management of heart failure in type 2 diabetes mellitus

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

Type 2 diabetes mellitus (T2DM) is a known predisposing factor for heart failure (HF). The growing burden of these two conditions and their impact on health of the individual and on society in general needs urgent attention from the health care professionals. Availability of multiple treatment choices for managing T2DM and HF may make therapeutic decisions more complex for clinicians. Recent cardiovascular outcome trials of antidiabetic drugs have added very robust evidence to effectively manage subjects with this dual condition. This consensus statement provides the prevalence trends and the impact of this dual burden on patients. In addition, it concisely narrates the types of HF, the different treatment algorithms, and recommendations for physicians to comprehensively manage such patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Kannel W, McGee D (1979) Diabetes and cardiovascular risk factors: the Framingham study. Circulation. 59:8–13

    Article  CAS  PubMed  Google Scholar 

  2. Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE (2018) The heart failure burden of type 2 diabetes mellitus—a review of pathophysiology and interventions. Heart Fail Rev 23:303–323

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Ingle L, Reddy P, Clark AL, Cleland JG (2006) Diabetes lowers six-minute walk test performance in heart failure. J Am Coll Cardiol 47:1909–1910

    Article  PubMed  Google Scholar 

  4. Egstrup M, Kistorp CN, Schou M, Høfsten DE, Møller JE, Tuxen CD, Gustafsson I (2013) Abnormal glucose metabolism is associated with reduced left ventricular contractile reserve and exercise intolerance in patients with chronic heart failure. Eur Heart J Cardiovasc Imaging 14:349–357

    Article  CAS  PubMed  Google Scholar 

  5. Kristensen SL, Mogensen UM, Jhund PS, Petrie MC, Preiss D, Win S, Køber L, McKelvie R, Zile MR, Anand IS, Komajda M, Gottdiener JS, Carson PE, McMurray J (2017) Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: a report from the I-Preserve trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation. 135:724–735

    Article  PubMed  Google Scholar 

  6. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basáñez MG, Baxter A, Bell ML, Benjamin EJ, Bennett D, Bernabé E, Bhalla K, Bhandari B, Bikbov B, Bin Abdulhak A, Birbeck G, Black JA, Blencowe H, Blore JD, Blyth F, Bolliger I, Bonaventure A, Boufous S, Bourne R, Boussinesq M, Braithwaite T, Brayne C, Bridgett L, Brooker S, Brooks P, Brugha TS, Bryan-Hancock C, Bucello C, Buchbinder R, Buckle G, Budke CM, Burch M, Burney P, Burstein R, Calabria B, Campbell B, Canter CE, Carabin H, Carapetis J, Carmona L, Cella C, Charlson F, Chen H, Cheng AT, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahiya M, Dahodwala N, Damsere-Derry J, Danaei G, Davis A, de Leo D, Degenhardt L, Dellavalle R, Delossantos A, Denenberg J, Derrett S, Des Jarlais DC, Dharmaratne SD, Dherani M, Diaz-Torne C, Dolk H, Dorsey ER, Driscoll T, Duber H, Ebel B, Edmond K, Elbaz A, Ali SE, Erskine H, Erwin PJ, Espindola P, Ewoigbokhan SE, Farzadfar F, Feigin V, Felson DT, Ferrari A, Ferri CP, Fèvre EM, Finucane MM, Flaxman S, Flood L, Foreman K, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabbe BJ, Gabriel SE, Gakidou E, Ganatra HA, Garcia B, Gaspari F, Gillum RF, Gmel G, Gosselin R, Grainger R, Groeger J, Guillemin F, Gunnell D, Gupta R, Haagsma J, Hagan H, Halasa YA, Hall W, Haring D, Haro JM, Harrison JE, Havmoeller R, Hay RJ, Higashi H, Hill C, Hoen B, Hoffman H, Hotez PJ, Hoy D, Huang JJ, Ibeanusi SE, Jacobsen KH, James SL, Jarvis D, Jasrasaria R, Jayaraman S, Johns N, Jonas JB, Karthikeyan G, Kassebaum N, Kawakami N, Keren A, Khoo JP, King CH, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lalloo R, Laslett LL, Lathlean T, Leasher JL, Lee YY, Leigh J, Lim SS, Limb E, Lin JK, Lipnick M, Lipshultz SE, Liu W, Loane M, Ohno SL, Lyons R, Ma J, Mabweijano J, MacIntyre M, Malekzadeh R, Mallinger L, Manivannan S, Marcenes W, March L, Margolis DJ, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty J, McDermott M, McGill N, McGrath J, Medina-Mora ME, Meltzer M, Mensah GA, Merriman TR, Meyer AC, Miglioli V, Miller M, Miller TR, Mitchell PB, Mocumbi AO, Moffitt TE, Mokdad AA, Monasta L, Montico M, Moradi-Lakeh M, Moran A, Morawska L, Mori R, Murdoch ME, Mwaniki MK, Naidoo K, Nair MN, Naldi L, Narayan KM, Nelson PK, Nelson RG, Nevitt MC, Newton CR, Nolte S, Norman P, Norman R, O’Donnell M, O’Hanlon S, Olives C, Omer SB, Ortblad K, Osborne R, Ozgediz D, Page A, Pahari B, Pandian JD, Rivero AP, Patten SB, Pearce N, Padilla RP, Perez-Ruiz F, Perico N, Pesudovs K, Phillips D, Phillips MR, Pierce K, Pion S, Polanczyk GV, Polinder S, Pope CA 3rd, Popova S, Porrini E, Pourmalek F, Prince M, Pullan RL, Ramaiah KD, Ranganathan D, Razavi H, Regan M, Rehm JT, Rein DB, Remuzzi G, Richardson K, Rivara FP, Roberts T, Robinson C, de Leòn FR, Ronfani L, Room R, Rosenfeld LC, Rushton L, Sacco RL, Saha S, Sampson U, Sanchez-Riera L, Sanman E, Schwebel DC, Scott JG, Segui-Gomez M, Shahraz S, Shepard DS, Shin H, Shivakoti R, Singh D, Singh GM, Singh JA, Singleton J, Sleet DA, Sliwa K, Smith E, Smith JL, Stapelberg NJ, Steer A, Steiner T, Stolk WA, Stovner LJ, Sudfeld C, Syed S, Tamburlini G, Tavakkoli M, Taylor HR, Taylor JA, Taylor WJ, Thomas B, Thomson WM, Thurston GD, Tleyjeh IM, Tonelli M, Towbin JA, Truelsen T, Tsilimbaris MK, Ubeda C, Undurraga EA, van der Werf M, van Os J, Vavilala MS, Venketasubramanian N, Wang M, Wang W, Watt K, Weatherall DJ, Weinstock MA, Weintraub R, Weisskopf MG, Weissman MM, White RA, Whiteford H, Wiersma ST, Wilkinson JD, Williams HC, Williams SR, Witt E, Wolfe F, Woolf AD, Wulf S, Yeh PH, Zaidi AK, Zheng ZJ, Zonies D, Lopez AD, Murray CJ, AlMazroa M, Memish ZA (2012) Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet. 380:2163–2196

  7. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CSP, Sato N, Shah AN, Gheorghiade M (2014) The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 63:1123–1133

    Article  PubMed  Google Scholar 

  8. Huffman MD, Prabhakaran D (2010) Heart failure: epidemiology and prevention in India. Natl Med J India 23:283–288

    PubMed  PubMed Central  Google Scholar 

  9. Institute of Health Metrics and Evaluation (2017) GBD compare. https://vizhub.healthdata.org/gbd-compare/ [Accessed 6th June 2019]

  10. Chaturvedi V, Parakh N, Seth S, Gupta N, Misra P, Rai SK, Anand K et al (2016) Heart failure in India: the INDUS (INDiaUkieri Study) study. J Pract Cardiovasc Sci 2:28–35

    Article  Google Scholar 

  11. Dokainish H, Teo K, Zhu J et al (2017) INTER-CHF Investigators. Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. Lancet Glob Health 5:e665–e672

    Article  PubMed  Google Scholar 

  12. Harikrishnan S, Sanjay G, Anees T et al (2015) Trivandrum Heart Failure Registry. Clinical presentation, management, in-hospital and 90-day outcomes of heart failure patients in Trivandrum, Kerala, India: the Trivandrum Heart Failure Registry. Eur J Heart Fail 17:794–800

    Article  PubMed  Google Scholar 

  13. Harikrishnan S, Sanjay G, Agarwal A, Kumar NP, Kumar KK, Bahuleyan CG, Vijayaraghavan G, Viswanathan S, Sreedharan M, Biju R, Rajalekshmi N, Nair T, Suresh K, Jeemon P (2017) One-year mortality outcomes and hospital readmissions of patients admitted with acute heart failure: data from the Trivandrum Heart Failure Registry in Kerala, India. Am Heart J 189:193–199

    Article  PubMed  Google Scholar 

  14. Lesyuk W, Kriza C, Kolominsky-Rabas P (2018) Cost-of-illness studies in heart failure: a systematic review 2004-2016. BMC Cardiovasc Disord 18:74

    Article  PubMed  PubMed Central  Google Scholar 

  15. Cook C, Cole G, Asaria P, Jabbour R, Francis DP (2014) The annual global economic burden of heart failure. Int J Cardiol 171:368–376

    Article  PubMed  Google Scholar 

  16. Einarson TR, Acs A, Ludwig C, Panton UH (2018) Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol 17:83

    Article  PubMed  PubMed Central  Google Scholar 

  17. Lawson CA, Solis-Trapala I, Dahlstrom U et al (2018) Comorbidity health pathways in heart failure patients: a sequences-of-regressions analysis using cross-sectional data from 10,575 patients in the Swedish Heart Failure Registry. PLoS Med 15:e1002540a

    Article  Google Scholar 

  18. Carrasco-Sánchez FJ, Gomez-Huelgas R, Formiga F et al (2014) RICA investigators. Association between type-2 diabetes mellitus and post-discharge outcomes in heart failure patients: findings from the RICA registry. Diabetes Res Clin Pract 104:410–419

    Article  PubMed  Google Scholar 

  19. Tromp J, Tay WT, Ouwerkerk W et al (2018) ASIAN-HF authors. Multimorbidity in patients with heart failure from 11 Asian regions: a prospective cohort study using the ASIAN-HF registry. PLoS Med 15:e1002541

    Article  PubMed  PubMed Central  Google Scholar 

  20. Mishra S, Mohan JC, Nair T, Chopra VK, Harikrishnan S, Guha S, Ramakrishnan S, Ray S, Sethi R, Samal UC, Sarat Chandra K, Hiremath MS, Banerjee AK, Kumar S, Das MK, Deb PK, Bahl VK (2018) Management protocols for chronic heart failure in India. Indian Heart J 70:105–127

    Article  CAS  PubMed  Google Scholar 

  21. Chopra VK, Mittal S, Bansal M, Singh B, Trehan N (2019) Clinical profile and one-year survival of patients with heart failure with reduced ejection fraction: the largest report from India. Indian Heart J. https://doi.org/10.1016/j.ihj.2019.07.008

  22. Wang Y, Negishi T, Negishi K, Marwick TH (2015) Prediction of heart failure in patients with type 2 diabetes mellitus-a systematic review and meta-analysis. Diabetes Res Clin Pract 108:55–66

    Article  PubMed  Google Scholar 

  23. Parry HM, Deshmukh H, Levin D, van Zuydam N, Elder DH, Morris AD, Struthers AD, Palmer CN, Doney AS, Lang CC (2015) Both high and low HbA1c predict incident heart failure in type 2 diabetes mellitus. Circ Heart Fail 8:236–242

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Schefold JC, Filippatos G, Hasenfuss G, Anker SD, von Haehling S (2016) Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev Nephrol 12:610–623

    Article  CAS  PubMed  Google Scholar 

  25. Lawson CA, Testani JM, Mamas M, Damman K, Jones PW, Teece L, Kadam UT (2018) Chronic kidney disease, worsening renal function and outcomes in a heart failure community setting: a UK national study. Int J Cardiol 267:120–127.b

    Article  PubMed  PubMed Central  Google Scholar 

  26. Kristensen SL, Preiss D, Jhund PS et al (2016) PARADIGM-HF Investigators and Committees.. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail 9:e002560.a

    Article  Google Scholar 

  27. Anjana RM, Pradeepa R, Deepa M et al (2011) ICMR–INDIAB Collaborative Study Group. Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: phase I results of the Indian Council of Medical Research-INdia DIABetes (ICMR-INDIAB) study. Diabetologia 54:3022–3027

    Article  CAS  PubMed  Google Scholar 

  28. Patel S, Nanda R, Abraham J, Sahoo S, Ganguly A, Mohapatra E (2017) Prediabetes and undiagnosed diabetes mellitus: the hidden danger. Indian J Med Biochem 21:91–95

    Article  Google Scholar 

  29. Serhiyenko VA, Serhiyenko AA (2018) Cardiac autonomic neuropathy: risk factors, diagnosis and treatment. World J Diabetes 9:1–24

    Article  PubMed  PubMed Central  Google Scholar 

  30. Nyström T, Santos-Pardo I, Hedberg F et al (2017) Effects on subclinical heart failure in type 2 diabetic subjects on liraglutide treatment vs. glimepiride both in combination with metformin: a randomized open parallel-group study. Front Endocrinol (Lausanne) 8:325

    Article  Google Scholar 

  31. König P, Mayer O, Bruthans J et al (2019) The prognostic importance of subclinical heart failure in stable coronary heart disease patients. Acta Cardiol 3:1–8

    Google Scholar 

  32. Rajput R, Jagdish SSB, Rattan A (2002) Echocardiographic and Doppler assessment of cardiac functions in patients of non-insulin dependent diabetes mellitus. JIACM 3:164–168

    Google Scholar 

  33. Faden G, Faganello G, De Feo S et al (2013) The increasing detection of asymptomatic left ventricular dysfunction in patients with type 2 diabetes mellitus without overt cardiac disease: data from the SHORTWAVE study. Diabetes Res Clin Pract 101:309–316

    Article  PubMed  Google Scholar 

  34. Schocken DD, Benjamin EJ, Fonarow GC et al (2008) American Heart Association Council on Epidemiology and Prevention; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Nursing; American Heart Association Council on High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; Functional Genomics and Translational Biology Interdisciplinary Working Group. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 117:2544–2565

    Article  PubMed  Google Scholar 

  35. Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D, Pinkett T, Ghali JK, Wilson AC (1996) Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 77:1017–1020

    Article  CAS  PubMed  Google Scholar 

  36. Wang TJ (2003) Natural history of asymptomatic left ventricular systolic dysfunction in the 3746 community. Circulation. 108:977–982

    Article  PubMed  Google Scholar 

  37. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW (2009) 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 119:e391–e479

    PubMed  Google Scholar 

  38. Yancy CW, Jessup M, Bozkurt B, American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines et al (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62:e147–e239

    Article  PubMed  Google Scholar 

  39. Ponikowski P, Voors AA, Anker SD et al (2016) Authors/Task Force Members; Document Reviewers.. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18:891–975

    Article  PubMed  Google Scholar 

  40. Johansson I, Dahlström U, Edner M, Näsman P, Rydén L, Norhammar A (2018) Type 2 diabetes and heart failure: characteristics and prognosis in preserved, mid-range and reduced ventricular function. Diab Vasc Dis Res 15:494–503

    Article  PubMed  Google Scholar 

  41. MacDonald MR, Petrie MC, Varyani F et al (2008) CHARM Investigators. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 29:1377–1385

    Article  PubMed  Google Scholar 

  42. Levelt E, Mahmod M, Piechnik SK, Ariga R, Francis JM, Rodgers CT, Clarke WT, Sabharwal N, Schneider JE, Karamitsos TD, Clarke K, Rider OJ, Neubauer S (2016) Relationship between left ventricular structural and metabolic remodeling in type 2 diabetes. Diabetes. 65:44–52

    CAS  PubMed  Google Scholar 

  43. Basta G, Schmidt AM, De Caterina R (2004) Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 63:582–592

    Article  CAS  PubMed  Google Scholar 

  44. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30:595–602

    Article  CAS  PubMed  Google Scholar 

  45. Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, Zuo F, Quan A, Farkouh ME, Fitchett DH, Goodman SG, Goldenberg RM, al-Omran M, Gilbert RE, Bhatt DL, Leiter LA, Jüni P, Zinman B, Connelly KA (2019) Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial. Circulation. 140(21):1693–1702

    Article  PubMed  Google Scholar 

  46. Brown AJM, Lang C, McCrimmon R, Struthers A et al (2019) A randomised controlled trial of dapagliflozin on left ventricular hypertrophy in patients with type two diabetes. The DAPA-LVH Trial. Circulation 140:A10643

    Google Scholar 

  47. Schilling JD (2015) The mitochondria in diabetic heart failure: from pathogenesis to therapeutic promise. Antioxid Redox Signal 22:1515–1526

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Kayama Y, Raaz U, Jagger A, Adam M, Schellinger IN, Sakamoto M, Suzuki H, Toyama K, Spin JM, Tsao PS (2015) Diabetic cardiovascular disease induced by oxidative stress. Int J Mol Sci 16:25234–25263

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Verma SK, Garikipati VNS, Kishore R (1863) Mitochondrial dysfunction and its impact on diabetic heart. Biochim Biophys Acta Mol basis Dis 2017:1098–1105

    Google Scholar 

  50. Chong CR, Clarke K, Levelt E (2017) Metabolic remodelling in diabetic cardiomyopathy. Cardiovasc Res 113:422–430

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Orsborne C, Chaggar PS, Shaw SM, Williams SG (2017) The renin-angiotensin-aldosterone system in heart failure for the non-specialist: the past, the present and the future. Postgrad Med J 93:29–37

    Article  CAS  PubMed  Google Scholar 

  52. Maack C, Lehrke M, Backs J, Heinzel FR, Hulot JS, Marx N, Paulus WJ, Rossignol P, Taegtmeyer H, Bauersachs J, Bayes-Genis A, Brutsaert D, Bugger H, Clarke K, Cosentino F, de Keulenaer G, Dei Cas A, González A, Huelsmann M, Iaccarino G, Lunde IG, Lyon AR, Pollesello P, Rena G, Riksen NP, Rosano G, Staels B, van Laake L, Wanner C, Farmakis D, Filippatos G, Ruschitzka F, Seferovic P, de Boer RA, Heymans S (2018) Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. Eur Heart J 39:4243–4254

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Yancy CW, Jessup M, Bozkurt B et al (2017) 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 136:e137–e161

    Article  PubMed  Google Scholar 

  54. Chow SL, Maisel AS, Anand I, American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Epidemiology and Prevention; Council on Functional Genomics and Translational Biology; and Council on Quality of Care and Outcomes Research et al (2017) Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Circulation 135:e1054–e1091

    Article  CAS  PubMed  Google Scholar 

  55. Nadar SK, Shaikh MM (2019) Biomarkers in routine heart failure clinical care. Card Fail Rev 5:50–56

    Article  PubMed  PubMed Central  Google Scholar 

  56. Maisel AS, Krishnaswamy P, Nowak RM et al (2002) Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347:161–167

    Article  CAS  PubMed  Google Scholar 

  57. Januzzi JL Jr, Camargo CA, Anwaruddin S et al (2005) The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95:948–954

    Article  CAS  PubMed  Google Scholar 

  58. Omar HR, Guglin M (2016) Discharge BNP is a stronger predictor of 6-month mortality in acute heart failure compared with baseline BNP and admission-to-discharge percentage BNP reduction. Int J Cardiol 221:1116–1122

    Article  PubMed  Google Scholar 

  59. Boisot S, Beede J, Isakson S, Chiu A, Clopton P, Januzzi J, Maisel AS, Fitzgerald RL (2008) Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail 14:732–738

    Article  PubMed  Google Scholar 

  60. Bayes-Genis A, Pascual-Figal D, Januzzi JL, Maisel A, Casas T, Valdés Chávarri M, Ordóñez-Llanos J (2010) Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure. Rev Esp Cardiol 63:1171–1178

    Article  PubMed  Google Scholar 

  61. Gehlken C, Suthahar N, Meijers WC, de Boer RA (2018) Galectin-3 in heart failure: an update of the last 3 years. Heart Fail Clin 14:75–92

    Article  PubMed  Google Scholar 

  62. Stelzle D, Shah ASV, Anand A, Strachan FE, Chapman AR, Denvir MA, Mills NL, McAllister D (2018) High-sensitivity cardiac troponin I and risk of heart failure in patients with suspected acute coronary syndrome: a cohort study. Eur Heart J Qual Care Clin Outcomes 4:36–42

    Article  PubMed  Google Scholar 

  63. Mishra S et al (2018) Indian Heart J 70:105–127

    Article  CAS  PubMed  Google Scholar 

  64. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T et al (2016) Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 29(4):277–314

    Article  PubMed  Google Scholar 

  65. Bajaj S (2018) RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017. Int J Diabetes Dev Ctries 38(Suppl 1):1–115

    Article  PubMed  Google Scholar 

  66. ADA (2020) Standards of medical care in diabetes—2020. Available from: https://care.diabetesjournals.org/content/diacare/suppl/2019/12/20/43.Supplement_1.DC1/DC_43_S1_2020.pdf. Accessed 20 Feb 2020

  67. AACE/ACE (2020) Consensus statement by The American Association Of Clinical Endocrinologists And American College Of Endocrinology on the comprehensive type 2 diabetes management algorithm–2020 executive summary. Available from: https://www.aace.com/pdfs/diabetes/algorithm-exec-summary.pdf. Accessed 20 Feb 2020

  68. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354:602]. Lancet 352:837–853

    Article  Google Scholar 

  69. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M et al (2008) ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572

    Article  CAS  PubMed  Google Scholar 

  70. The Action to Control Cardiovascular Risk in Diabetes Study Group (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559

    Article  PubMed Central  Google Scholar 

  71. Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Ge L, for the VADT Investigators et al; Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes [published correction appears in N Engl J Med. 2015;373:198]. N Engl J Med 2015;372:2197–2206

  72. Skrtic S, Cabrera C, Olsson M, Schnecke V, Lind M (2017) Contemporary risk estimates of three HbA1c variables in relation to heart failure following diagnosis of type 2 diabetes. Heart. 103:353–358

    Article  PubMed  CAS  Google Scholar 

  73. Lind M, Olsson M, Rosengren A, Svensson AM, Bounias I, Gudbjornsdottir S (2012) The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes. Diabetologia. 55:2946–2953

    Article  CAS  PubMed  Google Scholar 

  74. Blecker S, Park H, Katz SD (2016) Association of HbA1c with hospitalization and mortality among patients with heart failure and diabetes. BMC Cardiovasc Disord 16:99

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  75. Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ et al (2019) Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA 322(12):1155–1166

  76. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–322a

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Marso SP, Bain SC, Consoli A et al (2016) SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834–1844b

    Article  CAS  PubMed  Google Scholar 

  78. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, ELIXA Investigators et al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373(23):2247–2257

    Article  CAS  PubMed  Google Scholar 

  79. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF, EXSCEL Study Group (2017) Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377(13):1228–1239

    Article  CAS  PubMed  Google Scholar 

  80. Bethel MA, Patel RA, Merrill P, EXSCEL Study Group et al (2018) Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 6:105–113

    Article  PubMed  Google Scholar 

  81. Hernandez AF, Green JB, Janmohamed S, Harmony Outcomes committees and investigators et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392:1519–1529

    Article  CAS  PubMed  Google Scholar 

  82. Gerstein HC, Colhoun HM, Dagenais GR, REWIND Investigators et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394:121–130

    Article  CAS  PubMed  Google Scholar 

  83. Green JB, Bethel MA, Armstrong PW, TECOS Study Group et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373:232–242

    Article  CAS  PubMed  Google Scholar 

  84. Scirica BM, Braunwald E, Raz I, SAVOR-TIMI 53 Steering Committee and Investigators* et al (2014) Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 130:1579–1588

    Article  CAS  PubMed  Google Scholar 

  85. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL et al (2013) EXAMINE: alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:1327–1335

    Article  CAS  PubMed  Google Scholar 

  86. McMurray JJV, Ponikowski P, Bolli GB, VIVIDD Trial Committees and Investigators et al (2018) Effects of vildagliptin on ventricular function in patients with type 2 diabetes and heart failure: a randomized placebo-controlled trial. JACC Heart Fail 6:8–17

    Article  PubMed  Google Scholar 

  87. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire D, Wilding JPH, Sabatine MS (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 393:31–39

    Article  CAS  PubMed  Google Scholar 

  88. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128

    Article  CAS  PubMed  Google Scholar 

  89. Wiviott SD, Raz I, Bonaca MP, DECLARE–TIMI 58 Investigators et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347–357

    Article  CAS  PubMed  Google Scholar 

  90. Mahaffey KW, Neal B, Perkovic V et al (2018) CANVAS Program Collaborative Group. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation. 137:323–334

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire D, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD (2019) Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 139:2528–2536

    Article  CAS  PubMed  Google Scholar 

  92. Singh AK, Unnikrishnan AG, Zargar AH, Kumar A, Das AK, Saboo B, Sinha B, Gangopadhyay KK, Talwalkar PG, Ghosal S, Kalra S, Joshi S, Sharma SK, Sriram U, Mohan V (2019) Evidence based consensus on positioning of SGLT2i in type 2 diabetes mellitus in Indians. Diabetes Ther 10:393–428

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Solini A, Giannini L, Seghieri M et al (2017) Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Cardiovasc Diabetol 16:138

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  94. Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ (2016) SGLT2 inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms? Diabetologia. 59:1333–1339

    Article  PubMed  PubMed Central  Google Scholar 

  95. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets D, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM, DAPA-HF Trial Committees and Investigators (2019) DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995–2008

    Article  CAS  PubMed  Google Scholar 

  96. Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, et al Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003;41(9):1529–1538

  97. Granger CB, McMurray JJ, Yusuf S, CHARM Investigators and Committees et al (2003) Effect of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM Alternative trial. Lancet 362:772–776

    Article  CAS  PubMed  Google Scholar 

  98. Tai C, Gan T, Zou L, Sun Y, Zhang Y, Chen W (2017) Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 17:257

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  99. Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B, PARADIGM-HF Investigators and Committees et al (2016) Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail 9(1):e002560

  100. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341(10):709–717

  101. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, EMPHASIS-HF Study Group (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11–21

    Article  CAS  PubMed  Google Scholar 

  102. Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, Rhodes S, Barrett M, Fonarow GC, Greenberg B, Heidenreich PA, Knabel T, Konstam MA, Steimle A, Warner Stevenson L (2003) Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 41(9):1529–1538

    Article  CAS  PubMed  Google Scholar 

  103. Tsujimoto T, Sugiyama T, Shapiro MF, Noda M, Kajio H (2017) Risk of cardiovascular events in patients with diabetes mellitus on β-blockers. Hypertension. 70:103–110

    Article  CAS  PubMed  Google Scholar 

  104. Komajda M, Tavazzi L, Francq BG, SHIFT Investigators et al (2015) Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. Eur J Heart Fail 17:1294–1301

    Article  CAS  PubMed  Google Scholar 

  105. Investigators SOLVD, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325(5):293–302

    Article  Google Scholar 

  106. (1999) The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 353(9146):9–13

  107. MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 353:2001–2007

  108. Eichhorn EJ, Bristow MR (2001) The carvedilol prospective randomized cumulative survival (COPERNICUS) trial. Curr Control Trials Cardiovasc Med 2:20–23

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Dunlay SM, Roger VL, Redfield MM (2017) Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 14:591–602

    Article  PubMed  Google Scholar 

  110. Smaha LA, American Heart Association (2004) The American Heart Association get with the guidelines program. Am Heart J 148(Suppl):S46–S48

    Article  PubMed  Google Scholar 

  111. McHugh K, DeVore AD, Wu J, Matsouaka RA, Fonarow GC, Heidenreich PA, Yancy CW, Green JB, Altman N, Hernandez AF (2019) J Am Coll Cardiol 73(5):602–611

    Article  PubMed  Google Scholar 

  112. Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, Swedberg K, Yusuf S, Granger CB, Pfeffer MA, McMurray J, Solomon SD (2018) Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail 20:1230–1239

    Article  CAS  PubMed  Google Scholar 

  113. Aguilar D, Deswal A, Ramasubbu K, Mann DL, Bozkurt B (2010) Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus. Am J Cardiol 105:373–377

    Article  PubMed  Google Scholar 

  114. Zheng SL, Chan FT, Nabeebaccus AA, Shah AM, McDonagh T, Okonko DO, Ayis S (2018) Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart. 104(5):407–415

    Article  CAS  PubMed  Google Scholar 

  115. Solomon SD, JV, Anand IS et al (2019) Angiotensin-Neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381(17):1609–1620

  116. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J (2003) CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362:777–781

    Article  CAS  PubMed  Google Scholar 

  117. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359:2456–2467

    Article  CAS  PubMed  Google Scholar 

  118. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, PEP-CHF Investigators (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27:2338–2345

    Article  CAS  PubMed  Google Scholar 

  119. Edelmann F, Wachter R, Schmidt AG et al (2013) Aldo-DHF Investigators Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 309:781–791

    Article  CAS  PubMed  Google Scholar 

  120. Flather MD, Shibata MC, Coats AJ et al (2005) SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26:215–225

    Article  CAS  PubMed  Google Scholar 

  121. Yamamoto K, Origasa H, Hori M, J-DHF Investigators (2013) Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 15:110–118

    Article  CAS  PubMed  Google Scholar 

  122. Liu LC, Hummel YM, van der Meer P, Hoendermis ES et al (2017) Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension. Eur J Heart Fail 19:116–125

    Article  CAS  PubMed  Google Scholar 

  123. Bardy GH, Lee KL, Mark DB et al (2005) Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure. N Engl J Med 352:225–237

    Article  CAS  PubMed  Google Scholar 

  124. Moss AJ, Zareba W, Hall WJ et al (2002) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346:877–883

    Article  PubMed  Google Scholar 

  125. Ghali JK, Boehmer J, Feldman AM, Saxon LA, Demarco T, Carson P, Yong P, Galle EG, Leigh J, Ecklund FL, Bristow MR (2007 Nov) Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure. J Card Fail 13(9):769–773

    Article  PubMed  Google Scholar 

  126. Wittenberg SM, Cook JR, Hall WJ, McNitt S, Zareba W, Moss AJ (2005) Multicenter Automatic Defibrillator Implantation Trial. Comparison of efficacy of implanted cardioverter-defibrillator in patients with versus without diabetes mellitus. Am J Cardiol 96(3):417–419

    Article  PubMed  Google Scholar 

  127. Konstam MA, Gheorghiade M, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K (2007) Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 297:1319–1331

    Article  CAS  PubMed  Google Scholar 

  128. Matsuzaki M, Hori M, Izumu T, Fukunami M (2011) Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther 25(Suppl 1):S33–S45

    Article  PubMed  CAS  Google Scholar 

  129. Choi HM, Park MS, Youn JC (2019) Update on heart failure management and future directions. Korean J Intern Med 34:11–43

    Article  PubMed  Google Scholar 

  130. Gustafsson F, Guarracino F, Schwinger RHG (2017) The inodilator levosimendan as a treatment for acute heart failure in various settings. Eur Heart J Suppl 19(Suppl C):C2–C7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  131. Hutchings DC, Anderson SG, Caldwell JL, Trafford AW (2018) Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection? Heart. 104:1244–1250

    Article  CAS  PubMed  Google Scholar 

  132. Levine AR, Helbling NL, Chien N, Bachman TN, Simon MA, Gladwin MT (2018) Abstract 17077: acute hemodynamic effects of oral nitrite in pulmonary hypertension related to heart failure with preserved ejection fraction (PH-HFpEF). Circulation 138:A17077

    Article  Google Scholar 

  133. Teerlink JR, Felker GM, McMurray JJV, COSMIC-HF Investigators et al (2016) Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet 388:2895–2903

    Article  CAS  PubMed  Google Scholar 

  134. Machaj F, Dembowska E, Rosik J, Szostak B, Mazurek-Mochol M, Pawlik A (2019) New therapies for the treatment of heart failure: a summary of recent accomplishments. Ther Clin Risk Manag 15:147–155

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Maurer MS, Schwartz JH, Gundapaneni B et al (2018) ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379:1007–1016

    Article  CAS  PubMed  Google Scholar 

  136. Ridker PM, Everett BM, Thuren T, MacFadyen J, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ, CANTOS Trial Group (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377:1119–1131

    Article  CAS  PubMed  Google Scholar 

  137. Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, Yaroshinsky A, Zsebo KM, Dittrich H, Hajjar RJ, Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) Investigators (2011) Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID) a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation. 124:304–313

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  138. Zsebo K, Yaroshinsky A, Rudy JJ, Wagner K, Greenberg B, Jessup M, Hajjar RJ (2014) Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res 114:101–108

    Article  CAS  PubMed  Google Scholar 

  139. Tompkins BA, Rieger AC, Florea V et al (2018) Comparison of mesenchymal stem cell efficacy in ischemic versus nonischemic dilated cardiomyopathy. J Am Heart Assoc 7:e008460

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  140. Park M, Yoon YS (2018) Cardiac regeneration with human pluripotent stem cell-derived cardiomyocytes. Korean Circ J 48:974–988

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  141. Available at https://clinicaltrials.gov/ct2/show/NCT03057977 [Accessed on 5th June 2019]

  142. Available at https://clinicaltrials.gov/ct2/show/NCT03448419[Accessed on 5th June 2019]

  143. Available at https://clinicaltrials.gov/ct2/show/NCT03877237 [Accessed on 5th June 2019]

  144. Available at https://clinicaltrials.gov/ct2/show/NCT03066804 [Accessed on 5th June 2019]

  145. Available at https://clinicaltrials.gov/ct2/show/NCT02884206 [Accessed on 5th June 2019]

  146. Available at https://clinicaltrials.gov/ct2/show/NCT03037580 [Accessed on 5th June 2019]

  147. Available at https://clinicaltrials.gov/ct2/show/NCT01599117 [Accessed on 5th June 2019]

  148. Available at https://clinicaltrials.gov/ct2/show/NCT02713126 [Accessed on 5th June 2019]

  149. Available at https://clinicaltrials.gov/ct2/show/NCT03057951 [Accessed on 5th June 2019]

  150. Available at https://clinicaltrials.gov/ct2/show/NCT03448406 [Accessed on 5th June 2019]

  151. Available at https://clinicaltrials.gov/ct2/show/NCT03030235 [Accessed on 5th June 2019]

  152. Available at https://clinicaltrials.gov/ct2/show/NCT03877224 [Accessed on 5th June 2019]

  153. Available at https://clinicaltrials.gov/ct2/show/NCT03619213 [Accessed on 5th June 2019]

  154. Available at https://clinicaltrials.gov/ct2/show/NCT03416270 [Accessed on 5th June 2019]

Download references

Acknowledgements

The authors thank AstraZeneca Pharma India Ltd. for providing medical writing assistance in the development of this manuscript, in collaboration with Sciformix Technologies Pvt. Ltd.

Author information

Authors and Affiliations

  1. Batra Heart Centre and Dean Academics and Research of BHMRC, Batra Hospital & Medical Research Centre, 1, Tughlakabad Institutional Area, Mehrauli Badarpur Road, New Delhi, 110 062, India

    Upendra Kaul

  2. Heart Clinic, Kolkata, West Bengal, 700019, India

    Saumitra Ray

  3. Apollo First Med Hospitals, Chennai, 600 010, India

    D. Prabhakar

  4. Fortis Hospital, Mohali, Punjab, 160062, India

    Arun Kochar

  5. SAL Hospital & Medical Institute, Ahmedabad, Gujarat, 380054, India

    Kamal Sharma

  6. AMRI Hospital, Kolkata, West Bengal, 700029, India

    Prakash Kumar Hazra

  7. BLK Super Speciality Hospital, Pusa Road, Karol Bagh, New Delhi, 110005, India

    Subhash Chandra

  8. Cardiac Consultants, 502/503 Hem Arcade, Dr Yagnik Road, Yagnik Road, Rajkot, 360001, India

    Dharmesh Ramakant Bhai Solanki

  9. Peerless Hospital, Pancha Sayar Rd, Sahid Smirity Colony, Pancha Sayar, 700094, Kolkata, West Bengal, India

    Anjan Lal Dutta

  10. Cath Labs MSSH (East) Saket, Max Super Speciality Hospital, New Delhi, 110017, India

    Viveka Kumar

  11. Care Hospitals, Road No 1, Banjara Hills, Hyderabad, 500034, India

    M. Srinivas Rao

  12. Apollo Hospitals Greams Road Chennai, Apollo Hospitals 21, Greams Lane, Off Greams Road, Chennai, 600 006, India

    Abraham Oomman

  13. Apollo Hospitals, Plot No.1 A, Bhat GIDC Estate, Gandhinagar, Gujarat, 382428, India

    Sameer Dani

  14. Holy Family Hospital, Mumbai, 400 050, India

    Brian Pinto

  15. Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bangalore, 560 069, India

    T. R. Raghu

Authors
  1. Upendra Kaul
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Saumitra Ray
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Prabhakar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arun Kochar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kamal Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Prakash Kumar Hazra
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Subhash Chandra
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Dharmesh Ramakant Bhai Solanki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Anjan Lal Dutta
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Viveka Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M. Srinivas Rao
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Abraham Oomman
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Sameer Dani
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Brian Pinto
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. T. R. Raghu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Upendra Kaul.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kaul, U., Ray, S., Prabhakar, D. et al. Consensus document: management of heart failure in type 2 diabetes mellitus. Heart Fail Rev 26, 1037–1062 (2021). https://doi.org/10.1007/s10741-020-09955-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10741-020-09955-7

Keywords

Search

Navigation